NEW YORK (GenomeWeb News) — Genomic Health today said that Aetna has set payment rates for its Oncotype DX test for early-stage breast cancer patients.
Genomic Health said Aetna, which began covering the test in August, has set rates for all of its plans for breast cancer patients for the test, which quantifies the odds of breast cancer recurrence and predicts the chances of the effectiveness of chemotherapy treatment.